CROs/Service Providers

Never mind an IPO, inVentiv sells 50% stake to equity firm Advent

Monday, August 8, 2016

After indicating it was gearing up for an imminent initial public offering, CRO inVentiv Health last week went in a different direction. Instead, the equity group Advent International Corp. has purchased a 50% stake in the company, making Advent a co-owner of the CRO with Thomas H. Lee Partners, which bought inVentiv in 2010 for approximately $1.1 billion.
The deal values inVentiv at $3.8 billion.

[Read More]

Quintiles, DaVita Clinical Research partner

Tuesday, August 2, 2016

Quintiles, a provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners, a leader in kidney care, have announced a global strategic alliance. The alliance combines DaVita’s clinical care and expansive footprint of research sites with Quintiles’ operational delivery and therapeutic expertise in clinical trials.

[Read More]

INC Research launches Vaccine Catalyst Site Network

Thursday, July 28, 2016

INC Research Holdings, a global phase I to IV CRO, has launched the company’s Vaccine Catalyst Site network as part of its Catalyst program introduced earlier this year to strengthen collaborations with clinical research sites worldwide, ultimately enhancing patient focus and optimizing study delivery to drive improved predictability and increased efficiency for customers. INC selected 40 high-performing clinical research sites to participate in the initial launch of its Vaccine Catalyst Site network, which was formed to respond to the rapid growth and strong pipeline of vaccine studies.

[Read More]